Synthetic lethality and chemoresistance in cancer

Kimberly Maxfield, Angelique Whitehurst

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Despite great strides in the development of anti-cancer strategies over the last 50 years, treatment regimens continue to cause significant toxicity and fail to fully eradicate disease. Enhancing the current state of therapy will require: (1) the expansion of available tumor selective and therapeutically tractable molecular targets, (2) the development of methods to provide a rational approach to identifying effective combinatorial drug cocktails, and (3) molecular markers that can accurately predict sensitive patient populations. To this end, efforts that reveal the molecular architecture supporting tumorigenic phenotypes are essential. RNA interference (RNAi)-mediated loss of function screens have emerged as a method for wholesale identification of tumor-specific dependencies that modulate chemo responsiveness. Here, we provide a broad overview of how genome-scale RNAi screening is being implemented. Cancer chemotherapy Cytotoxic chemotherapy Goodman and Gilman's 1946 discovery that lymphosarcomas respond to nitrogen mustard demonstrated that tumor cells may have an enhanced sensitivity to chemical poisons as compared to their normal counterparts. This finding revolutionized cancer treatment as it indicated that in addition to radiation and surgery, the only available modalities at the time, drugs could also be administered to reduce tumor burden (Goodman et al. 1946). Following on these initial observations, over the ensuing 50 years, an arsenal of cytotoxic agents were developed to treat a range of cancer types (Chabner and Roberts 2005, Strebhardt and Ullrich 2008). The majority of these agents, as with the nitrogen mustard, share a common characteristic: they induce genomic damage. For example, agents such as cisplatin cause inter-and intrastrand DNA cross links. This DNA damage can lead to the inhibition of cell division by activating an arrest in the cell cycle to allow for DNA repair through the nucleotide excision repair (NER) pathway. This pathway is coupled to apoptotic programs that are activated if overwhelming damage is detected (Plunkett et al. 1995, Siddik 2003, Wang and Lippard 2005).

Original languageEnglish (US)
Title of host publicationSystems Genetics: Linking Genotypes and Phenotypes
PublisherCambridge University Press
Pages65-82
Number of pages18
ISBN (Print)9781139012751, 9781107013841
DOIs
StatePublished - Jan 1 2015

Fingerprint

Tumors
Mechlorethamine
Chemotherapy
Cells
DNA
Neoplasms
Repair
RNA
Arsenals
Oncology
RNA Interference
Poisons
Cytotoxins
DNA Repair
Pharmaceutical Preparations
Surgery
Cisplatin
Toxicity
Screening
Nucleotides

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Maxfield, K., & Whitehurst, A. (2015). Synthetic lethality and chemoresistance in cancer. In Systems Genetics: Linking Genotypes and Phenotypes (pp. 65-82). Cambridge University Press. https://doi.org/10.1017/CBO9781139012751.005

Synthetic lethality and chemoresistance in cancer. / Maxfield, Kimberly; Whitehurst, Angelique.

Systems Genetics: Linking Genotypes and Phenotypes. Cambridge University Press, 2015. p. 65-82.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maxfield, K & Whitehurst, A 2015, Synthetic lethality and chemoresistance in cancer. in Systems Genetics: Linking Genotypes and Phenotypes. Cambridge University Press, pp. 65-82. https://doi.org/10.1017/CBO9781139012751.005
Maxfield K, Whitehurst A. Synthetic lethality and chemoresistance in cancer. In Systems Genetics: Linking Genotypes and Phenotypes. Cambridge University Press. 2015. p. 65-82 https://doi.org/10.1017/CBO9781139012751.005
Maxfield, Kimberly ; Whitehurst, Angelique. / Synthetic lethality and chemoresistance in cancer. Systems Genetics: Linking Genotypes and Phenotypes. Cambridge University Press, 2015. pp. 65-82
@inbook{c1aebddfdc7b4baf8087cf8152a1f10d,
title = "Synthetic lethality and chemoresistance in cancer",
abstract = "Despite great strides in the development of anti-cancer strategies over the last 50 years, treatment regimens continue to cause significant toxicity and fail to fully eradicate disease. Enhancing the current state of therapy will require: (1) the expansion of available tumor selective and therapeutically tractable molecular targets, (2) the development of methods to provide a rational approach to identifying effective combinatorial drug cocktails, and (3) molecular markers that can accurately predict sensitive patient populations. To this end, efforts that reveal the molecular architecture supporting tumorigenic phenotypes are essential. RNA interference (RNAi)-mediated loss of function screens have emerged as a method for wholesale identification of tumor-specific dependencies that modulate chemo responsiveness. Here, we provide a broad overview of how genome-scale RNAi screening is being implemented. Cancer chemotherapy Cytotoxic chemotherapy Goodman and Gilman's 1946 discovery that lymphosarcomas respond to nitrogen mustard demonstrated that tumor cells may have an enhanced sensitivity to chemical poisons as compared to their normal counterparts. This finding revolutionized cancer treatment as it indicated that in addition to radiation and surgery, the only available modalities at the time, drugs could also be administered to reduce tumor burden (Goodman et al. 1946). Following on these initial observations, over the ensuing 50 years, an arsenal of cytotoxic agents were developed to treat a range of cancer types (Chabner and Roberts 2005, Strebhardt and Ullrich 2008). The majority of these agents, as with the nitrogen mustard, share a common characteristic: they induce genomic damage. For example, agents such as cisplatin cause inter-and intrastrand DNA cross links. This DNA damage can lead to the inhibition of cell division by activating an arrest in the cell cycle to allow for DNA repair through the nucleotide excision repair (NER) pathway. This pathway is coupled to apoptotic programs that are activated if overwhelming damage is detected (Plunkett et al. 1995, Siddik 2003, Wang and Lippard 2005).",
author = "Kimberly Maxfield and Angelique Whitehurst",
year = "2015",
month = "1",
day = "1",
doi = "10.1017/CBO9781139012751.005",
language = "English (US)",
isbn = "9781139012751",
pages = "65--82",
booktitle = "Systems Genetics: Linking Genotypes and Phenotypes",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Synthetic lethality and chemoresistance in cancer

AU - Maxfield, Kimberly

AU - Whitehurst, Angelique

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite great strides in the development of anti-cancer strategies over the last 50 years, treatment regimens continue to cause significant toxicity and fail to fully eradicate disease. Enhancing the current state of therapy will require: (1) the expansion of available tumor selective and therapeutically tractable molecular targets, (2) the development of methods to provide a rational approach to identifying effective combinatorial drug cocktails, and (3) molecular markers that can accurately predict sensitive patient populations. To this end, efforts that reveal the molecular architecture supporting tumorigenic phenotypes are essential. RNA interference (RNAi)-mediated loss of function screens have emerged as a method for wholesale identification of tumor-specific dependencies that modulate chemo responsiveness. Here, we provide a broad overview of how genome-scale RNAi screening is being implemented. Cancer chemotherapy Cytotoxic chemotherapy Goodman and Gilman's 1946 discovery that lymphosarcomas respond to nitrogen mustard demonstrated that tumor cells may have an enhanced sensitivity to chemical poisons as compared to their normal counterparts. This finding revolutionized cancer treatment as it indicated that in addition to radiation and surgery, the only available modalities at the time, drugs could also be administered to reduce tumor burden (Goodman et al. 1946). Following on these initial observations, over the ensuing 50 years, an arsenal of cytotoxic agents were developed to treat a range of cancer types (Chabner and Roberts 2005, Strebhardt and Ullrich 2008). The majority of these agents, as with the nitrogen mustard, share a common characteristic: they induce genomic damage. For example, agents such as cisplatin cause inter-and intrastrand DNA cross links. This DNA damage can lead to the inhibition of cell division by activating an arrest in the cell cycle to allow for DNA repair through the nucleotide excision repair (NER) pathway. This pathway is coupled to apoptotic programs that are activated if overwhelming damage is detected (Plunkett et al. 1995, Siddik 2003, Wang and Lippard 2005).

AB - Despite great strides in the development of anti-cancer strategies over the last 50 years, treatment regimens continue to cause significant toxicity and fail to fully eradicate disease. Enhancing the current state of therapy will require: (1) the expansion of available tumor selective and therapeutically tractable molecular targets, (2) the development of methods to provide a rational approach to identifying effective combinatorial drug cocktails, and (3) molecular markers that can accurately predict sensitive patient populations. To this end, efforts that reveal the molecular architecture supporting tumorigenic phenotypes are essential. RNA interference (RNAi)-mediated loss of function screens have emerged as a method for wholesale identification of tumor-specific dependencies that modulate chemo responsiveness. Here, we provide a broad overview of how genome-scale RNAi screening is being implemented. Cancer chemotherapy Cytotoxic chemotherapy Goodman and Gilman's 1946 discovery that lymphosarcomas respond to nitrogen mustard demonstrated that tumor cells may have an enhanced sensitivity to chemical poisons as compared to their normal counterparts. This finding revolutionized cancer treatment as it indicated that in addition to radiation and surgery, the only available modalities at the time, drugs could also be administered to reduce tumor burden (Goodman et al. 1946). Following on these initial observations, over the ensuing 50 years, an arsenal of cytotoxic agents were developed to treat a range of cancer types (Chabner and Roberts 2005, Strebhardt and Ullrich 2008). The majority of these agents, as with the nitrogen mustard, share a common characteristic: they induce genomic damage. For example, agents such as cisplatin cause inter-and intrastrand DNA cross links. This DNA damage can lead to the inhibition of cell division by activating an arrest in the cell cycle to allow for DNA repair through the nucleotide excision repair (NER) pathway. This pathway is coupled to apoptotic programs that are activated if overwhelming damage is detected (Plunkett et al. 1995, Siddik 2003, Wang and Lippard 2005).

UR - http://www.scopus.com/inward/record.url?scp=84954211706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954211706&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139012751.005

DO - 10.1017/CBO9781139012751.005

M3 - Chapter

AN - SCOPUS:84954211706

SN - 9781139012751

SN - 9781107013841

SP - 65

EP - 82

BT - Systems Genetics: Linking Genotypes and Phenotypes

PB - Cambridge University Press

ER -